| Not Yet Recruiting | Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic St NCT06943664 | Roswell Park Cancer Institute | Phase 2 |
| Recruiting | Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung C NCT06096844 | National Cancer Institute (NCI) | Phase 3 |
| Withdrawn | Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung NCT05412875 | Ohio State University Comprehensive Cancer Center | N/A |
| Recruiting | SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Ca NCT05570825 | University of Washington | Phase 2 |
| Active Not Recruiting | Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer NCT05340309 | University of Southern California | Phase 2 |
| Suspended | Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) NCT04929041 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Terminated | Remote Monitoring With Health-Coaching for Lifestyle Changes in Patients With Lung Cancer Related Fatigue NCT05407038 | Mayo Clinic | N/A |
| Active Not Recruiting | Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small C NCT05334329 | University of California, Irvine | Phase 1 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual NCT05096663 | SWOG Cancer Research Network | Phase 2 / Phase 3 |
| Active Not Recruiting | Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer NCT05166616 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic NCT05017025 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy NCT04372927 | University of Washington | Phase 2 |
| Recruiting | Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer NCT05136846 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or NCT04940299 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial NCT04789681 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chem NCT04892953 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Mo NCT05010109 | M.D. Anderson Cancer Center | N/A |
| Terminated | Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Canc NCT04971187 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progress NCT04902040 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients NCT04705025 | Jonsson Comprehensive Cancer Center | N/A |
| Terminated | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metasta NCT04785287 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Pos NCT04837716 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | A Nurse-Led Intervention for Fear of Progression in Advanced Cancer NCT04819997 | City of Hope Medical Center | N/A |
| Recruiting | Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer NCT03819296 | M.D. Anderson Cancer Center | Phase 1 |
| Withdrawn | Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Pro NCT05022394 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-s NCT04751747 | Rutgers, The State University of New Jersey | N/A |
| Active Not Recruiting | NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer NCT04505267 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carc NCT04701307 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Sol NCT04771520 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer NCT04396535 | Mayo Clinic | Phase 2 |
| Completed | Family Caregivers in Underserved Populations Providing Complex Cancer Care NCT05213078 | City of Hope Medical Center | N/A |
| Active Not Recruiting | Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer NCT04428905 | City of Hope Medical Center | Phase 3 |
| Active Not Recruiting | Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standa NCT04092283 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCL NCT04227028 | City of Hope Medical Center | Phase 1 |
| Terminated | Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced L NCT03735095 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lun NCT04073745 | Roswell Park Cancer Institute | Phase 1 |
| Withdrawn | [18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing P NCT04186988 | University of California, Davis | EARLY_Phase 1 |
| Completed | Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes NCT04183218 | Mayo Clinic | — |
| Active Not Recruiting | Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small L NCT04013542 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study NCT04430725 | M.D. Anderson Cancer Center | — |
| Completed | Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study NCT03707574 | National Cancer Institute (NCI) | — |
| Terminated | Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer NCT03995667 | OHSU Knight Cancer Institute | Phase 2 |
| Active Not Recruiting | Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer NCT03939481 | SWOG Cancer Research Network | — |
| Active Not Recruiting | Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non- NCT03793179 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Geriatric and Quality of Life Assessments in Older Patients With Non-metastatic or Metastatic Head and Neck or NCT03902535 | City of Hope Medical Center | — |
| Active Not Recruiting | Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage S NCT03830918 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non NCT03948100 | M.D. Anderson Cancer Center | N/A |
| Completed | Patient Portal and Navigation Program in Providing Information for Asian American Cancer Patients NCT03867916 | University of California, San Francisco | N/A |
| Completed | Embedded Palliative Care in Managing Symptoms in Participants With Recurrent Stage III-IV Thoracic Malignancie NCT04662645 | Ohio State University Comprehensive Cancer Center | N/A |
| Active Not Recruiting | Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer NCT03637816 | M.D. Anderson Cancer Center | Phase 2 / Phase 3 |
| Active Not Recruiting | Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small NCT03731585 | M.D. Anderson Cancer Center | N/A |
| Completed | Conquer Fear SUPPORT Intervention in Supporting Patients With Stage III-IV Lung or Gynecologic Cancer NCT03776253 | City of Hope Medical Center | N/A |
| Completed | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies NCT03590054 | Rahul Aggarwal | Phase 1 |
| Active Not Recruiting | Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic NCT03225664 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung C NCT02983578 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or NCT02955290 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Terminated | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherap NCT02419495 | M.D. Anderson Cancer Center | Phase 1 |